AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21900836
Drug: Pemetrexed 500
RxNorm normalized name: pemetrexed 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500 mg/m2 IV, carboplatin AUC=5 IV, and bevacizumab 15 mg/kg IV (day 1 of 21‐day cycles)
Trial: 19328723
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with platelet counts < 100 x 10(9)/L
Trial: 2720578
Drug: Controlled-release morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release morphine sulfate preparation (MS Contin tablets) administered every 12 hours
Trial: 2720578
Drug: Morphine oral
RxNorm normalized name: morphine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine oral solution (MOS) administered every 4 hours
Trial: 29745627
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (PT) for two weeks
Trial: 24204744
Drug: MEDI‐559 (live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI‐559 (live attenuated intranasal vaccine)
Trial: 21914136
Drug: Tadalafil (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (40 mg for 6 weeks)
Trial: 16407639
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg oral sustained‐release theophylline plus budesonide (200 microg b.i.d.)
Trial: 16407639
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg montelukast plus budesonide (200 microg b.i.d.)
Trial: 16407639
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose of inhaled budesonide (400 microg b.i.d.)
Trial: 14525750
Drug: Computerized ED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized ED discharge instructions with National Highway Traffic Safety Administration recommendations for motor vehicle CRDs
Trial: 9170417
Drug: Acute myeloid
RxNorm normalized name: A cd33/cd3 bispecific t-cell engager antibody for acute myeloid leukemia therapy
DrugBank: Eluvixtamab (DB17252)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute myeloid leukemia with afebrile neutropenia from chemotherapy
Trial: 1439640
Drug: Intraaortic protamine
RxNorm normalized name: protamines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraaortic protamine administration (group A)
Trial: 1439640
Drug: Intravenous protamine
RxNorm normalized name: protamines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous protamine administration (group V)
Trial: 31615996
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose carbon monoxide exposure (100-200 ppm) for 12 weeks
Trial: 30360964
Drug: Ixekizumab Q2W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab Q2W (80 mg subcutaneous every two weeks)
Trial: 30360964
Drug: Ixekizumab Q4W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab Q4W (80 mg subcutaneous every four weeks)
Trial: 30360964
Drug: Adalimumab (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (40 mg Q2W)
Trial: 24452879
Drug: Oxycodone/naloxone prolonged-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone/naloxone prolonged-release (PR)
Trial: 24452879
Drug: Oxycodone/naloxone PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone/naloxone PR
Trial: 22582911
Drug: Methyl aminolevulinate
RxNorm normalized name: Methyl aminolevulinate
DrugBank: Methyl aminolevulinate (DB00992)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methyl aminolevulinate (MAL) plus red light therapy
Trial: 22582911
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus red light therapy
Trial: 19620877
Drug: Etravirine 200
RxNorm normalized name: etravirine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etravirine 200 mg twice daily
Trial: 15578800
Drug: Academic medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Academic medicine
Trial: 7633189
Drug: 0.35 mg
RxNorm normalized name: nicotine 0.35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.35 mg kg‐1 day‐1 prednisolone for six months
Trial: 1688515
Drug: ThioTEPA (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ThioTEPA (30 mg) in distilled water
Trial: 1688515
Drug: ThioTEPA (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ThioTEPA (30 mg) in 10% (v/v) Tween 80 (30 ml)
Trial: 28071
Drug: Penbutolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penbutolol (40 mg b.i.d.)
Trial: 28071
Drug: Propranolol (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (160 mg b.i.d.)
Trial: 25484179
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (ESL) 800-2400mg, once-daily
Trial: 25484179
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (ESL) 600-1800mg, once-daily
Trial: 25484179
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (ESL) 900mg, once-daily (during recurrence prevention study)
Trial: 25484179
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (ESL) 300, 900, and 1800mg, once-daily (during recurrence prevention study)
Trial: 15785941
Drug: Intravenous calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous calcitriol (Calcijex) administered as a bolus injection three times a week for up to 12 weeks, with initial doses of 0.5-1.5 microg based on severity of secondary HPT.
Trial: 15785941
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered three times a week for up to 12 weeks.
Trial: 15785941
Drug: Intravenous calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous calcitriol (Calcijex)
Trial: 12151929
Drug: TA 50
RxNorm normalized name: Denta 5000 Plus
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TA 50 mg/kg over 15 min with 1 mg x kg(‐1) x hr(‐1) maintenance infusion for 10 h
Trial: 12151929
Drug: TA 100
RxNorm normalized name: NUCYNTA 100mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TA 100 mg/kg over 15 min with 1 mg x kg(‐1) x hr(‐1) maintenance infusion for 10 h
Trial: 12151929
Drug: TA 10
RxNorm normalized name: Zebeta 10mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TA 10 mg/kg over 15 min with 1 mg x kg(‐1) x hr(‐1) maintenance infusion for 10 h
Trial: 12151929
Drug: Simulation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulation of previous studies with a 30‐min loading dose of 12.5 mg/kg and maintenance infusion of 6.5 mg x kg(‐1) x hr(‐1)
Trial: 12151929
Drug: Simulation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulation of previous studies with a 30 mg/kg loading dose plus 16 mg x kg(‐1) x h(‐1) continuous infusion
Trial: 28584913
Drug: Triazolam 0.250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam 0.250 mg
Trial: 8824695
Drug: Triazolam 0.375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam 0.375 mg
Trial: 6265109
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cyclophosphamide (500 mg/m2 I.V.), Adriamycin (50 mg/m2 I.V.), DTIC (250 mg/m2 I.V.), and vincristine (1 mg/m2 I.V.) every 4 weeks for three cycles followed by the same combination every 4 weeks for an additional six cycles.
Trial: 6265109
Drug: Non-cross-resistant drug
RxNorm normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-cross-resistant drug combination of BCNU (100 mg/m2 I.V.), procarbazine (100 mg/m2 p.o. daily x 10 days), methotrexate (25 mg/m2 I.V.), and vinblastine (5 mg/m2 I.V.) every 4 weeks for six cycles.
Trial: 6265109
Drug: Alternating treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating treatments with the two regimens for a total of six cycles of therapy.
Trial: 31544471
Drug: Empirical intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical intravenous vancomycin
Trial: 31084291
Drug: NAVIGATE (early
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAVIGATE (early intervention treatment model)
Trial: 28778815
Drug: Etoricoxib 60
RxNorm normalized name: etoricoxib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 60 mg/day for 14 days
Trial: 23598371
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg candesartan in the first week, and 32 mg candesartan in the second and third week
Trial: 6137969
Drug: Midazolam 0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.10 mg/kg
Trial: 9585306
Drug: Midazolam 0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.08 mg/kg
Trial: 7664702
Drug: Midazolam 0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.06 mg/kg
Trial: 9585306
Drug: Midazolam 0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.04 mg/kg
Trial: 8029790
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose aspirin (A)
Trial: 8029790
Drug: Low intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low intensity oral anticoagulation with warfarin (W)
Trial: 8029790
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with warfarin and aspirin (WA)
Trial: 8029790
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (WA), Warfarin (W), Aspirin (A)
Trial: 21668835
Drug: 1% topical
RxNorm normalized name: SSD 1% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% topical clindamycin phosphate
Trial: 17004893
Drug: B. polyfermenticus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B. polyfermenticus tablets at a dose of 3.1 x 10(8) colony-forming units/day for 8 weeks
Trial: 17004893
Drug: B. polyfermenticus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B. polyfermenticus tablets
Trial: 10493339
Drug: Reduced osmolarity
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced osmolarity ORS (224 mmol/l)
Trial: 10493339
Drug: Standard ORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ORS (311 mmol/l)
Trial: 2066768
Drug: 0.25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg oral dextroamphetamine
Trial: 6354828
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of oral omeprazole
Trial: 6354828
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of oral omeprazole
Trial: 6354828
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg of oral omeprazole
Trial: 30144099
Drug: Vixotrigine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vixotrigine (400 mg for men, 300 mg for women) administered orally twice daily for 36 days
Trial: 30144099
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally twice daily for 36 days
Trial: 21986094
Drug: s.c. denosumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. denosumab (120 mg) every 4 weeks
Trial: 21986094
Drug: i.v. zoledronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. zoledronic acid (4 mg) every 4 weeks
Trial: 19995510
Drug: Group II:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II: bevelling the margins of buccal fissures (0.5 mm bevel) after enameloplasty
Trial: 18094378
Drug: Telbivudine 600
RxNorm normalized name: telbivudine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine 600 mg once daily
Trial: 18094378
Drug: Lamivudine 100
RxNorm normalized name: lamivudine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 100 mg once daily
Trial: 8340736
Drug: Promethazine 50
RxNorm normalized name: promethazine 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazine 50 mg and calcium 1000 mg daily
Trial: 8340736
Drug: Calcium 1000
RxNorm normalized name: RITE AID Calcium 1000mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium 1000 mg daily
Trial: 23307164
Drug: Dexmedetomidine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.25 μg/kg
Trial: 23259263
Drug: Salbutamol aerosol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol aerosol, 200 microg, less than 8 sprays in 24 h
Trial: 20009958
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment plus self-care
Trial: 1841669
Drug: Propanolol 80
RxNorm normalized name: Propanolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propanolol 80 mg
Trial: 31584525
Drug: Intralesional saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional saline injection
Trial: 26328787
Drug: Morphine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine + Vecuronium
Trial: 24849043
Drug: Sublingual testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual testosterone (0.5 mg) followed by buspirone (10 mg) tablet
Trial: 24849043
Drug: Combination tablet
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination tablet of testosterone and buspirone
Trial: 14597456
Drug: Leech therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leech therapy (4 to 6 locally applied leeches)
Trial: 14597456
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac therapy (28-day regimen)
Trial: 30636672
Drug: Leech therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leech therapy
Trial: 10748449
Drug: Pretherapeutic hyperprolactinemia
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretherapeutic hyperprolactinemia (PRL >/=15.0 ng/mL)
Trial: 3891189
Drug: Aluminum hydroxide
RxNorm normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminum hydroxide gel (30 ml)
Trial: 31050156
Drug: Low 1,5-AG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low 1,5-AG level (<39.7 μmol/L)
Trial: 16186434
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg DRSP/1 mg E2
Trial: 12013355
Drug: Piperacillin 4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin 4.0 g-tazobactam 0.5 g administered every 8 hours
Trial: 12013355
Drug: Piperacillin 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin 3.0 g-tazobactam 0.375 g administered every 6 hours
Trial: 12013355
Drug: Piperacillin 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin 3.0 g-tazobactam 0.375 g every 4 hours
Trial: 12013355
Drug: Piperacillin 4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin 4.0 g-tazobactam 0.5 g every 6 hours
Trial: 12013355
Drug: Continuous-infusion piperacillin
RxNorm normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous-infusion piperacillin 12 g-tazobactam 1.5 g/day
Trial: 10202313
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 6 microm monodisperse Teflon particles labelled with 111In after bronchial provocation with allergen
Trial: 10202313
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 6 microm monodisperse Teflon particles labelled with 111In (control measurement)
Trial: 2281671
Drug: anxiolytic drug
RxNorm normalized name: ANXIOLYTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anxiolytic drug
Trial: 26156269
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic administration with vibration
Trial: 26156269
Drug: Injections without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injections without the use of vibration
Trial: 22484576
Drug: FEC (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEC (3 courses of fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2), and cyclophosphamide 500 mg/m(2)) followed by DOC (3 courses of docetaxel 100 mg/m(2))
Trial: 22484576
Drug: DOC (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOC (3 courses of docetaxel 100 mg/m(2)) followed by FEC (3 courses of fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2), and cyclophosphamide 500 mg/m(2))
Trial: 16923097
Drug: Fentanyl 2
RxNorm normalized name: fentanyl 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 2 microg/kg, Midazolam 0.03 mg/kg, Propofol 2.5 mg/kg (group FMP)
Trial: 16923097
Drug: Fentanyl 2
RxNorm normalized name: fentanyl 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 2 microg/kg, Lignocaine 1.5 mg/kg, Propofol 2.5 mg/kg (group FLP)
Trial: 12784100
Drug: Duloxetine 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 80 mg q.d.
Trial: 12784100
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg b.i.d.
Trial: 12784100
Drug: Desipramine 50
RxNorm normalized name: desipramine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine 50 mg b.i.d.
Trial: 10864586
Drug: L‐NMMA (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NMMA (3 mg/kg priming dose + 3 mg/kg per h)
Trial: 10864586
Drug: HOI superimposed
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HOI superimposed on L‐NMMA infusion
Trial: 10864586
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion (time control)
Trial: 10864586
Drug: HOI without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HOI without L‐NMMA infusion
Trial: 8875556
Drug: alpha-tocopherol acetate
RxNorm normalized name: alpha-Tocopherol acetate
DrugBank: alpha-Tocopherol acetate (DB14003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: alpha-tocopherol acetate (125 mg/g) applied twice daily for three months
Trial: 8875556
Drug: difluoromethylornithine cream
RxNorm normalized name: α-difluoromethylornithine
DrugBank: Eflornithine (DB06243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: difluoromethylornithine cream applied twice daily for three months
Trial: 1843365
Drug: Quassia Amarga
RxNorm normalized name: QUASSIA
DrugBank: Quassia (DB13263)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quassia Amarga (alcoholic solution)
Trial: 29518094
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous insulin lispro infusion (CSII)
Trial: 29518094
Drug: Once-daily insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily insulin isophane
Trial: 26682871
Drug: Doublet chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doublet chemotherapy in the low-risk group (GH >67)
Trial: 26682871
Drug: Doublet chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doublet chemotherapy in the intermediate-risk group (46 ≤ GH ≤ 67)
Trial: 26682871
Drug: Doublet chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doublet chemotherapy in the high-risk group (GH <46)
Trial: 24456362
Drug: Doenjang (9.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doenjang (9.8 g/day)
Trial: 15775733
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) 0.625 mg conjugated equine estrogens (CEE) combined with 2.5 mg medroxyprogesterone
Trial: 15775733
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of HRT and Simvastatin (20 mg)
Trial: 16369229
Drug: Simvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (20 mg)
Trial: 10559578
Drug: budesonide‐printed polyester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: budesonide‐printed polyester squares in serial doses (150‐0.074 microg/cm(2))
Trial: 7586263
Drug: 80-cc can
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80-cc can size
Trial: 7586263
Drug: 60-cc can
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60-cc can size
Trial: 7586263
Drug: 40-cc can
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40-cc can size
Trial: 2122037
Drug: Oral branched-chain
RxNorm normalized name: Machilus thunbergii branch extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral branched-chain amino acids (BCAA)